Livforsakringsbolaget Skandia Omsesidigt cut its stake in Danaher Co. (NYSE:DHR – Free Report) by 1.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 5,807 shares of the conglomerate’s stock after selling 100 shares during the period. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Danaher were worth $1,334,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently modified their holdings of DHR. Heck Capital Advisors LLC purchased a new stake in Danaher during the fourth quarter worth $27,000. Decker Retirement Planning Inc. acquired a new position in shares of Danaher during the 4th quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new stake in Danaher in the 3rd quarter valued at about $39,000. MidAtlantic Capital Management Inc. purchased a new position in Danaher during the 3rd quarter valued at about $40,000. Finally, FSA Wealth Management LLC acquired a new position in Danaher during the third quarter worth about $50,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Price Performance
DHR opened at $209.95 on Friday. The company has a 50 day moving average of $233.96 and a two-hundred day moving average of $252.39. The company has a quick ratio of 1.05, a current ratio of 1.40 and a debt-to-equity ratio of 0.31. Danaher Co. has a 52-week low of $209.10 and a 52-week high of $281.70. The company has a market cap of $151.64 billion, a P/E ratio of 39.76, a P/E/G ratio of 2.80 and a beta of 0.83.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were paid a $0.27 dividend. The ex-dividend date was Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.51%. Danaher’s dividend payout ratio (DPR) is presently 20.45%.
Insider Transactions at Danaher
In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The shares were sold at an average price of $224.13, for a total value of $1,277,541.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. Insiders own 10.90% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the stock. Scotiabank began coverage on shares of Danaher in a research note on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price objective for the company. UBS Group reduced their price objective on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a research report on Wednesday, October 23rd. Stifel Nicolaus lifted their price objective on Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research report on Wednesday, October 23rd. Guggenheim began coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Finally, Barclays lowered their price target on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating for the company in a report on Thursday, January 30th. Seven investment analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $278.00.
View Our Latest Stock Report on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- Manufacturing Stocks Investing
- These are the 3 Stocks Most Likely to Split in 2025
- What is the Dow Jones Industrial Average (DJIA)?
- Price Plunge in Roblox Presents Opportunity for Robust Gains
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Billions in Buybacks: 4 Stocks Rewarding Shareholders Now
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.